Walgreens Boots Alliance (WBA)

Walgreens Boots Alliance is a global leader in retail and wholesale pharmacy, touching millions of lives every day through dispensing and distributing medicines, and through its convenient retail locations, digital platforms and health and beauty products. The company has more than 100 years of trusted health care heritage and innovation in community pharmacy and pharmaceutical wholesaling. Including equity method investments, WBA has a presence in more than 25 countries, employs more than 450,000 people and has more than 21,000 stores. WBA's purpose is to help people across the world lead healthier and happier lives. The company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. WBA is included in FORTUNE's 2020 list of the World's Most Admired Companies*, ranked first in the food and drugstore category. This is the 27th consecutive year that WBA or its predecessor company, Walgreen Co., has been named to the list.

Company profile

Stefano Pessina
Fiscal year end
Walgreen Arizona Drug Co. • Walgreens Boots Alliance Holdings LLC • Waltrust Properties, Inc. • Walgreens Specialty Pharmacy, LLC • Prime Therapeutics Specialty Pharmacy LLC • WBA Investments, Inc. • WBA Financial, LLC • Alliance Healthcare Deutschland AG • Walgreens Boots Alliance (Hong Kong) Investments Limited • Walgreen Co. ...

WBA stock data


30 Jun 22
12 Aug 22
31 Aug 22
Quarter (USD) May 22 Feb 22 Nov 21 Aug 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Aug 21 Aug 20 Aug 19 Aug 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 4.54B 4.54B 4.54B 4.54B 4.54B 4.54B
Cash burn (monthly) (no burn) (no burn) 106.67M (no burn) (no burn) (no burn)
Cash used (since last report) n/a n/a 256.2M n/a n/a n/a
Cash remaining n/a n/a 4.28B n/a n/a n/a
Runway (months of cash) n/a n/a 40.2 n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
13 Jul 22 Brailer David J Phantom Stock Units Common Stock Grant Acquire A No No 37.24 805.585 30K 63,995.81
13 Jul 22 Lederer John Anthony Phantom Stock Units Common Stock Grant Acquire A No No 37.24 671.321 25K 38,944.64
13 Jul 22 Murphy Dominic Phantom Stock Units Common Stock Grant Acquire A No No 37.24 671.321 25K 49,483.47
13 Jul 22 Jarrett Valerie B Phantom Stock Units Common Stock Grant Acquire A No No 37.24 671.321 25K 8,510
11 May 22 Walgreens Boots Alliance Common Stock Sell Dispose S Yes No 150 6,000,000 900M 52,854,867
73.5% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1277 1341 -4.8%
Opened positions 98 235 -58.3%
Closed positions 162 105 +54.3%
Increased positions 553 475 +16.4%
Reduced positions 424 448 -5.4%
13F shares Current Prev Q Change
Total value 27.81B 31.47B -11.6%
Total shares 635.44M 636.24M -0.1%
Total puts 11.42M 13.98M -18.3%
Total calls 8.63M 14.18M -39.1%
Total put/call ratio 1.3 1.0 +34.1%
Largest owners Shares Value Change
Alliance Sante Participations 144.79M $5.84B 0.0%
Vanguard 59M $2.64B -0.4%
BLK Blackrock 57.75M $2.59B +4.9%
STT State Street 49.82M $2.23B +6.2%
Capital World Investors 21.5M $962.73M -0.1%
FMR 15.54M $695.59M -8.1%
Geode Capital Management 12.8M $571.69M +3.8%
IVZ Invesco 9.12M $408.48M +7.1%
WFC Wells Fargo & Co. 8.91M $398.72M +53.0%
NTRS Northern Trust 8.33M $372.89M -3.4%
Largest transactions Shares Bought/sold Change
Aristotle Capital Management 7.95K -10.25M -99.9%
Norges Bank 0 -7.13M EXIT
WFC Wells Fargo & Co. 8.91M +3.08M +53.0%
STT State Street 49.82M +2.91M +6.2%
BLK Blackrock 57.75M +2.72M +4.9%
FHI Federated Hermes 5.23M +2.26M +76.3%
AMP Ameriprise Financial 3.64M +2.18M +150.3%
Schroder Investment Management 2.19M +2.15M +5365.3%
Allianz Asset Management GmbH 6.45M +1.9M +41.7%
Point72 Asset Management 0 -1.67M EXIT

Financial report summary

  • Global health developments and economic uncertainty resulting from the COVID-19 pandemic have adversely impacted, and may continue to adversely impact, our business, results of operations, cash flows and financial position.
  • Reductions in third-party reimbursement levels, from private or governmental agency plans, and potential changes in industry pricing benchmarks for prescription drugs could materially and adversely affect our results of operations.
  • A shift in pharmacy mix toward lower margin plans, products and programs could adversely affect our results of operations.
  • We derive a significant portion of our sales in the U.S. from prescription drug sales reimbursed by a limited number of pharmacy benefit management companies.
  • We could be adversely affected by a decrease in the introduction of new brand name and generic prescription drugs as well as increases in the cost to procure prescription drugs.
  • Consolidation and strategic alliances in the healthcare industry could adversely affect our business operations, competitive positioning, financial condition and results of operations.
  • Our business results depend on our ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives.
  • Changes in economic conditions could adversely affect consumer buying practices.
  • The industries in which we operate are highly competitive and constantly evolving and changes in market dynamics could adversely impact us.
  • If we do not successfully develop and maintain a relevant omni-channel experience for our customers, our businesses and results of operations could be adversely impacted.
  • If the merchandise and services that we offer fail to meet customer needs, our sales may be adversely affected.
  • Our substantial international business operations subject us to a number of operating, economic, political, regulatory and other international business risks.
  • Disruption in our global supply chain could negatively impact our businesses.
  • We outsource certain business processes to third-party vendors that subject us to risks, including disruptions in business and increased costs.
  • We use a single wholesaler of branded and generic pharmaceutical drugs as our primary source of such products.
  • Failure to retain and recruit, or failure to manage succession of, key personnel could have an adverse impact on our future performance.
  • We may be unable to keep existing store locations or open new locations in desirable places on favorable terms, which could materially and adversely affect our results of operations.
  • Our business and operations are subject to risks related to climate change.
  • We may not be successful in executing elements of our business strategy, which may have a material adverse impact on our business and financial results.
  • Our growth strategy is partially dependent upon our ability to identify and successfully complete acquisitions, joint ventures and other strategic partnerships and alliances.
  • The anticipated strategic and financial benefits of our relationship with AmerisourceBergen may not be realized.
  • From time to time, we make investments in companies over which we do not have sole control and some of these companies may operate in sectors that differ from our current operations and have different risks.
  • A significant disruption in our information technology and computer systems or those of businesses we rely on could harm us.
  • We are subject to payment-related and other financial services risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and potentially disrupt our business operations.
  • We have significant outstanding debt; our debt and associated payment obligations could significantly increase in the future if we incur additional debt and do not retire existing debt.
  • As a holding company, we are dependent on funding from our operating subsidiaries to pay dividends and other obligations.
  • Our quarterly results may fluctuate significantly based on seasonality and other factors.
  • We have a substantial amount of goodwill and other intangible assets which could, in the future, become impaired and result in material non-cash charges to our results of operations.
  • We are exposed to risks associated with foreign currency exchange rate fluctuations.
  • We could be adversely impacted by changes in assumptions used in calculating pension assets and liabilities.
  • Changes in the healthcare industry and regulatory environments may adversely affect our businesses.
  • We are exposed to risks related to litigation and other legal proceedings.
  • A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability.
  • We could be adversely affected by violations of anti-bribery, anti-corruption and/or international trade laws.
  • We could be adversely affected by product liability, product recall, personal injury or other health and safety issues.
  • We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
  • Certain stockholders may have significant voting influence over matters requiring stockholder approval.
  • Conflicts of interest, or the appearance of conflicts of interest, may arise because certain of our directors and officers are also owners or directors of companies we may have dealings with.
  • Our certificate of incorporation and bylaws, Delaware law or our agreements with certain stockholders may impede the ability of our stockholders to make changes to our Board or impede a takeover.
  • We cannot guarantee that our stock repurchase program will be fully implemented or that it will enhance long-term stockholder value.
Management Discussion
  • The Company's United States segment includes the Walgreens business which includes the operations of retail drugstores, health and wellness services, and mail and central specialty pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise.
  • 1See “Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.

Content analysis

8th grade Avg
New words: absence, admission, aforementioned, category, chain, composing, Computershare, conclusion, constitute, defense, escrow, exporting, Fargo, indenture, indirect, indirectly, inflow, judgement, modest, peak, penalty, permissible, pertaining, petition, remediation, renamed, restitution, satisfied, Sequoyah, Simultaneously, successor, unutilized, voluntary, Yen
Removed: approach, continuation, European, execution, pandemic, Pasco, pretax, Union


Cosmetic skincare compositions
29 Mar 22
According to the present invention there is provided a cosmetic composition comprising: (i) a salicylic acid compound; (ii) monoammonium glycyrrhizate; and (iii) a polyphenolic antioxidant agent.
Cosmetic O/W Mascara Compositions Comprising Polyurethane Resin
3 Mar 22
According to the present invention there is provided a stable, fluid, tubing mascara composition in the form of an oil-water emulsion comprising: (i) at least 9% by weight of the total composition of one or more film-forming aliphatic polyurethane resins; and (ii) one or more waxes; wherein the ratio of total aliphatic polyurethane resin concentration to total wax concentration is between 0.70 and 0.92.
Skin care composition and method thereof
5 Oct 21
The disclosed technology relates to a composition comprising: 0.1 to 3 wt % (or 0.5 to 2.5 wt %) of a beta hydroxy acid, 0.05 to 3 wt % (or 0.09 to 2.5 wt %) of an O-substituted ascorbic acid or a derivative thereof, and a cosmetically acceptable medium comprising an aqueous phase, wherein a beta hydroxy acid is present at a higher concentration than O-substituted ascorbic acid or a derivative thereof.
Cosmetic Compositions
12 Aug 21
Inventors: Emma Billinger, David Fowler, Melanie Lewis
Cosmetic Preservative System
15 Jul 21
According to the present invention there is provided a cosmetic composition comprising a cosmetically acceptable carrier and a preservative system, wherein the preservative system comprises: (i) an antimicrobial agent; (ii) a chelating agent comprising ethylenediamine tetraacetic acid (EDTA) or a derivative thereof; and (iii) an antimicrobial booster agent selected from the group consisting of ethylhexylglycerin, caprylyl glycol, hydroxy acetophenone, caprylhydroxamic acid, phenethyl alcohol, p-anisic acid, glyceryl caprylate, levulinic acid, sodium levulinate, propanediol, hexanediol, pentylene glycol, capryloyl glycine, methylpropanediol, phenylpropanol, sodium anisate, and combinations thereof, wherein the antimicrobial agent is present in an amount of from about 0.001% to about 1% by weight of the composition.